SCHEMBL3105440

SCHEMBL3105440

CC(O)C1([N+](=O)[O-])C=CC=CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Alcohol SCHEMBL6832438 0.98
SCHEMBL1665467 0.86
SCHEMBL1030937 0.86
SCHEMBL1665420 0.83
SCHEMBL17593230 0.78
SCHEMBL3212979 0.67
Ethane SCHEMBL27535133 0.67
SCHEMBL4254172 0.67
SCHEMBL28815353 0.67
SCHEMBL27801237 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180221508-A1 COMPOSITIONS AND METHODS FOR IMMUNOMODULATION TVA (ABC), LLC 2018-08-09 US claimed
US-20180221503-A1 COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES TVA (ABC), LLC 2018-08-09 US claimed
EP-3328363-A1 COMPOSITIONS AND METHODS FOR IMMUNOMODULATION Tarveda Therapeutics, Inc. (US) 2018-06-06 EP claimed
EP-3328377-A1 COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES Tarveda Therapeutics, Inc. (US) 2018-06-06 EP claimed
WO-2017023749-A1 COMPOSITIONS AND METHODS FOR IMMUNOMODULATION TARVEDA THERAPEUTICS, INC. (US) 2017-02-09 WO claimed
WO-2017023779-A1 COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES TARVEDA THERAPEUTICS, INC. (US) 2017-02-09 WO claimed
EP-0871673-B1 BISPECIFIC ANTIBODIES IN WHICH THE BINDING CAPABILITY IS REVERSIBLY INHIBITED BY A PHOTOCLEAVABLE MOIETY BIOENHANCEMENTS LTD (GB) 2006-04-05 EP claimed
US-20040197336-A1 Bispecific antibodies in which the binding capability is reversibly inhibited by a photocleavable moiety SELF COLIN HENRY (GB) 2004-10-07 US claimed
EP-0871673-A1 BISPECIFIC ANTIBODIES IN WHICH THE BINDING CAPABILITY IS REVERSIBLY INHIBITED BY A PHOTOCLEAVABLE MOIETY Bioenhancementsments Ltd. (GB) 1998-10-21 EP claimed
WO-1996034892-A1 BISPECIFIC ANTIBODIES IN WHICH THE BINDING CAPABILITY IS REVERSIBLY INHIBITED BY A PHOTOCLEAVABLE MOIETY BIOENHANCEMENTS LTD. (GB) 1996-11-07 WO claimed
US-20180221503-A1 COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES TVA (ABC), LLC 2018-08-09 US disclosed
US-20180221508-A1 COMPOSITIONS AND METHODS FOR IMMUNOMODULATION TVA (ABC), LLC 2018-08-09 US disclosed
EP-3328363-A1 COMPOSITIONS AND METHODS FOR IMMUNOMODULATION Tarveda Therapeutics, Inc. (US) 2018-06-06 EP disclosed
EP-3328377-A1 COMPOSITIONS AND METHODS FOR IMMUNO-ONCOLOGY THERAPIES Tarveda Therapeutics, Inc. (US) 2018-06-06 EP disclosed
WO-2017023749-A1 COMPOSITIONS AND METHODS FOR IMMUNOMODULATION TARVEDA THERAPEUTICS, INC. (US) 2017-02-09 WO disclosed
EP-1723418-A2 BINDING AGENTS Bioenhancementsments Ltd. (GB) 2006-11-22 EP disclosed
EP-0871673-B1 BISPECIFIC ANTIBODIES IN WHICH THE BINDING CAPABILITY IS REVERSIBLY INHIBITED BY A PHOTOCLEAVABLE MOIETY BIOENHANCEMENTS LTD (GB) 2006-04-05 EP disclosed
WO-2005083431-A2 BINDING AGENTS BLOENHANCEMENTS LIMITED (GB) 2005-09-09 WO disclosed
EP-0871673-A1 BISPECIFIC ANTIBODIES IN WHICH THE BINDING CAPABILITY IS REVERSIBLY INHIBITED BY A PHOTOCLEAVABLE MOIETY Bioenhancementsments Ltd. (GB) 1998-10-21 EP disclosed
WO-1996034892-A1 BISPECIFIC ANTIBODIES IN WHICH THE BINDING CAPABILITY IS REVERSIBLY INHIBITED BY A PHOTOCLEAVABLE MOIETY BIOENHANCEMENTS LTD. (GB) 1996-11-07 WO disclosed